var data={"title":"Fondaparinux: Dosing and adverse effects","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Fondaparinux: Dosing and adverse effects</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Kenneth A Bauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> (Arixtra) is a synthetic anticoagulant based on the pentasaccharide sequence that makes up the minimal antithrombin (AT) binding region of heparin. Similar to low molecular weight heparins, it is an indirect inhibitor of factor Xa, but it does not inhibit thrombin at all. Fondaparinux has a longer half-life than heparin and does not interact with platelets, both of which may be advantageous in certain settings.</p><p>This topic review discusses the dosing and adverse effects associated with <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>, including dosing in patients with renal insufficiency and management of bleeding.</p><p>Indications for <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> are presented in separate topic reviews:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Deep vein thrombosis and pulmonary embolism &ndash; (See <a href=\"topic.htm?path=venous-thromboembolism-initiation-of-anticoagulation-first-10-days\" class=\"medical medical_review\">&quot;Venous thromboembolism: Initiation of anticoagulation (first 10 days)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superficial vein thrombosis &ndash; (See <a href=\"topic.htm?path=phlebitis-and-thrombosis-of-the-superficial-lower-extremity-veins\" class=\"medical medical_review\">&quot;Phlebitis and thrombosis of the superficial lower extremity veins&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thromboprophylaxis (medical patients) &ndash; (See <a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-acutely-ill-hospitalized-medical-adults\" class=\"medical medical_review\">&quot;Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thromboprophylaxis (surgical patients) &ndash; (See <a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-surgical-patients\" class=\"medical medical_review\">&quot;Prevention of venous thromboembolic disease in surgical patients&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute coronary syndrome &ndash; (See <a href=\"topic.htm?path=anticoagulant-therapy-in-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Anticoagulant therapy in non-ST elevation acute coronary syndromes&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heparin-induced thrombocytopenia (HIT) &ndash; (See <a href=\"topic.htm?path=management-of-heparin-induced-thrombocytopenia\" class=\"medical medical_review\">&quot;Management of heparin-induced thrombocytopenia&quot;</a>.)</p><p/><p>Information for other anticoagulants is also presented separately: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heparins &ndash; (See <a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Heparin and LMW heparin: Dosing and adverse effects&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">Warfarin</a> and other vitamin K antagonists &ndash; (See <a href=\"topic.htm?path=warfarin-and-other-vkas-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Warfarin and other VKAs: Dosing and adverse effects&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Direct oral anticoagulants &ndash; (See <a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PHARMACOLOGY</span></p><p class=\"headingAnchor\" id=\"H1736413\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> consists of a highly sulfated pentasaccharide derived from the minimal antithrombin (AT)-binding region of heparin. It is an indirect factor Xa inhibitor (<a href=\"image.htm?imageKey=HEME%2F94856\" class=\"graphic graphic_figure graphicRef94856 \">figure 1</a>). It acts by binding to and inducing a conformational change in AT that increases the ability of AT to inactivate factor Xa (<a href=\"image.htm?imageKey=HEME%2F101832\" class=\"graphic graphic_figure graphicRef101832 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> binds to AT with a higher affinity (dissociation constant 50 nmol) than the native pentasaccharide of <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">unfractionated heparin</a> or low molecular weight heparin, and it causes a conformational change in AT that significantly increases the ability of AT to inactivate factor Xa. The binding of fondaparinux to AT is stoichiometric (1:1), and reversible [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> cannot bind to or inactivate thrombin (factor IIa) because it cannot form a ternary complex with AT and thrombin (<a href=\"image.htm?imageKey=HEME%2F101832\" class=\"graphic graphic_figure graphicRef101832 \">figure 2</a>). Ternary complex formation requires pentasaccharide-containing chains at least 18 saccharide units long, such as those present in <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">unfractionated heparin</a> and, to a lesser extent, low molecular weight heparin preparations. (See <a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects#H3\" class=\"medical medical_review\">&quot;Heparin and LMW heparin: Dosing and adverse effects&quot;, section on 'Mechanisms of action'</a>.)</p><p/><p><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> does not bind to or interact with other plasma proteins or cellular elements. Specifically, fondaparinux does not interact with platelets or platelet factor 4, and thus, unlike heparin, is not expected to be capable of inducing a heparin-induced thrombocytopenia (HIT)-like syndrome [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/6-11\" class=\"abstract_t\">6-11</a>]. In the major trials evaluating the use of fondaparinux for thromboprophylaxis, no cases of HIT were observed [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/8\" class=\"abstract_t\">8</a>]. Several case series describe the effective use of fondaparinux in the setting of HIT [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/12-16\" class=\"abstract_t\">12-16</a>]. However, there are rare case reports of HIT in which fondaparinux was administered [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/17-20\" class=\"abstract_t\">17-20</a>]. The use of fondaparinux in HIT is described separately. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-heparin-induced-thrombocytopenia#H8927918\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of heparin-induced thrombocytopenia&quot;, section on 'Pathophysiology'</a> and <a href=\"topic.htm?path=management-of-heparin-induced-thrombocytopenia#H39\" class=\"medical medical_review\">&quot;Management of heparin-induced thrombocytopenia&quot;, section on 'Fondaparinux'</a>.)</p><p class=\"headingAnchor\" id=\"H4208184561\"><span class=\"h2\">Metabolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> is 100 percent bioavailable after subcutaneous injection, with half-maximal and peak serum concentrations reached in 25 minutes and 1.7 hours following subcutaneous injection, respectively [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/21\" class=\"abstract_t\">21</a>]. The half-life of fondaparinux is 15 to 17 hours. Anticoagulant activity persists for about three to five half-lives following discontinuation of fondaparinux, or a period of two to four days in individuals with normal renal function.</p><p>The majority of an administered dose of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> is cleared by the kidney, and excreted unchanged in the urine. Clearance of this drug is reduced in individuals with reduced creatinine clearance, and use is not recommended in individuals with creatinine clearance &lt;30 <span class=\"nowrap\">mL/min</span>. (See <a href=\"#H1579490054\" class=\"local\">'Indications and contraindications'</a> below.)</p><p><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> metabolism is not affected by hepatic failure; however, patients with hepatic failure may be at increased risk of hemorrhage due to a number of hemostatic changes. (See <a href=\"topic.htm?path=hemostatic-abnormalities-in-patients-with-liver-disease\" class=\"medical medical_review\">&quot;Hemostatic abnormalities in patients with liver disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1677004280\"><span class=\"h2\">Long-acting analogs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Attempts to develop long-acting analogs of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> have not resulted in any clinically approved agents. The following drugs were evaluated in phase III trials.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idraparinux was a longer half-life analog of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> that could be given subcutaneously once per week. Development was halted due to an increased risk of bleeding in nonvalvular atrial fibrillation; decreased efficacy was also found in pulmonary embolism, as compared with standard therapy [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/22-24\" class=\"abstract_t\">22-24</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idrabiotaparinux (SSR 126517) is a biotinylated version of idraparinux that could be neutralized by intervenous infusion of avidin, which binds <a href=\"topic.htm?path=biotin-vitamin-h-pediatric-drug-information\" class=\"drug drug_pediatric\">biotin</a> [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/25-28\" class=\"abstract_t\">25-28</a>].</p><p/><p class=\"headingAnchor\" id=\"H3065436885\"><span class=\"h2\">Advantages and disadvantages compared with other anticoagulants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of anticoagulant should be based on evidence for the clinical setting. In settings in which <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> is considered clinically equivalent with other anticoagulants, the following advantages and disadvantages may be worth considering:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Advantages</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Longer half-life allows once daily dosing</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Lack of platelet interaction makes risk of HIT negligible</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Monitoring not required with routine use</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disadvantages</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Must be given parenterally</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>No specific antidote or reversal agent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Lack of ability to monitor at most centers due to lack of wide availability of fondaparinux-calibrated anti-factor Xa levels</p><p/><p class=\"headingAnchor\" id=\"H1579490054\"><span class=\"h1\">INDICATIONS AND CONTRAINDICATIONS</span></p><p><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> is used for venous thromboembolism (VTE) prophylaxis in a number of medical and perioperative settings. Evidence for its efficacy and comparison with other anticoagulants is discussed in separate topic reviews on the specific clinical setting:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Surgical patients</strong> &ndash; (See <a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-surgical-patients\" class=\"medical medical_review\">&quot;Prevention of venous thromboembolic disease in surgical patients&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Medical patients</strong> &ndash; (See <a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-acutely-ill-hospitalized-medical-adults\" class=\"medical medical_review\">&quot;Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Patients with VTE</strong> &ndash; (See <a href=\"topic.htm?path=overview-of-the-treatment-of-lower-extremity-deep-vein-thrombosis-dvt\" class=\"medical medical_review\">&quot;Overview of the treatment of lower extremity deep vein thrombosis (DVT)&quot;</a> and <a href=\"topic.htm?path=venous-thromboembolism-anticoagulation-after-initial-management\" class=\"medical medical_review\">&quot;Venous thromboembolism: Anticoagulation after initial management&quot;</a> and <a href=\"topic.htm?path=venous-thromboembolism-initiation-of-anticoagulation-first-10-days\" class=\"medical medical_review\">&quot;Venous thromboembolism: Initiation of anticoagulation (first 10 days)&quot;</a>.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Patients with superficial vein thrombosis</strong> &ndash; (See <a href=\"topic.htm?path=phlebitis-and-thrombosis-of-the-superficial-lower-extremity-veins\" class=\"medical medical_review\">&quot;Phlebitis and thrombosis of the superficial lower extremity veins&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Patients with acute coronary syndromes</strong> &ndash; (See <a href=\"topic.htm?path=anticoagulant-therapy-in-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Anticoagulant therapy in non-ST elevation acute coronary syndromes&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Patients with heparin-induced thrombocytopenia (HIT)</strong> &ndash; (See <a href=\"topic.htm?path=management-of-heparin-induced-thrombocytopenia\" class=\"medical medical_review\">&quot;Management of heparin-induced thrombocytopenia&quot;</a>.)</p><p/><p>We generally avoid using <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> in the following patient groups:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnant women, unless there is a contraindication to heparin (see <a href=\"#H488749887\" class=\"local\">'Pregnancy'</a> below)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with a creatinine clearance &lt;30 <span class=\"nowrap\">mL/min</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals weighing &lt;50 kg, in the prophylactic setting (dose reduction is used in the therapeutic setting for individuals &lt;50 kg)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with bacterial endocarditis or other relative or absolute contraindication for an anticoagulant</p><p/><p>Additional possible contraindications that apply to the use of anticoagulants in general are listed in the table (<a href=\"image.htm?imageKey=HEME%2F107527\" class=\"graphic graphic_table graphicRef107527 \">table 1</a>); this is not intended to substitute for the judgement of the treating clinician who can weigh the risks and benefits for the individual patient.</p><p>A lower dose of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> typically is used in patients weighing &lt;50 kg receiving fondaparinux for VTE therapy. (See <a href=\"#H6\" class=\"local\">'Dosing'</a> below.)</p><p>Therapy is individualized for those with thrombocytopenia depending on the reason for thrombocytopenia and the estimated bleeding risk. As an example, we may avoid using <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> in individuals with a platelet count <span class=\"nowrap\">&lt;70,000/microL</span> due to bone marrow suppression, but if thrombocytopenia is due to HIT, the platelet count is expected to rise and it may be appropriate to give fondaparinux since the major concern is thrombosis rather than bleeding.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DOSING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> is given subcutaneously once daily. The dose in individuals with normal renal function is based on body weight and the indication for anticoagulant use (eg, prophylaxis for venous thromboembolism [VTE] versus therapy) [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/29\" class=\"abstract_t\">29</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>VTE prophylaxis or acute coronary syndromes</strong> &ndash; 2.5 mg once daily. In the perioperative setting, the first dose is given six to eight hours postoperatively (after skin closure), as done in all of the major clinical trials. A 1.5 mg dose is available for orthopedic VTE prophylaxis in Europe but not in the United States. The 1.5 mg dose is suggested for individuals with creatinine clearance of 20 to 50 <span class=\"nowrap\">mL/min,</span> although safety and efficacy of this dose has not been well-studied. (See <a href=\"#H495387621\" class=\"local\">'Elective surgery'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Superficial vein thrombosis (treatment)</strong> &ndash; 2.5 mg once daily. Duration of therapy and other interventions are presented separately. (See <a href=\"topic.htm?path=phlebitis-and-thrombosis-of-the-superficial-lower-extremity-veins#H20\" class=\"medical medical_review\">&quot;Phlebitis and thrombosis of the superficial lower extremity veins&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>VTE (treatment)</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients weighing &lt;50 kg &ndash; 5 mg once daily</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients weighing 50 to 100 kg &ndash; 7.5 mg once daily</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients weighing &gt;100 kg &ndash; 10 mg once daily</p><p/><p>The duration of therapy is discussed in topic reviews on the specific indications. (See <a href=\"#H1579490054\" class=\"local\">'Indications and contraindications'</a> above.)</p><p><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> cannot be given intramuscularly.</p><p class=\"headingAnchor\" id=\"H4004533291\"><span class=\"h1\">MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> does not require monitoring in routine clinical use. Monitoring of drug levels or coagulation testing was not performed in clinical trials.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drug levels</strong> &ndash; In cases where monitoring is needed (eg, prior to neurosurgery or spine surgery, extremes of very high or very low body weight), anti-factor Xa activity can be measured approximately four hours after the dose is administered. The anti-factor Xa activity assay must be calibrated using <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> as a reference standard. Results are presented as fondaparinux levels in <span class=\"nowrap\">mcg/mL</span>. The therapeutic range has not been established, but typical levels are in the range of 0.2 to 0.4 <span class=\"nowrap\">mcg/mL</span> for prophylactic dose fondaparinux and 0.5 to 1.5 <span class=\"nowrap\">mcg/mL</span> for therapeutic dose fondaparinux. Communication with the testing laboratory is advised.</p><p/><p class=\"bulletIndent1\">The activated partial thromboplastin time (aPTT) cannot be used to monitor <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>, although it may become prolonged at therapeutic doses.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Renal function</strong> &ndash; Renal function should be assessed before starting <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>, because patients with impaired renal function may require a dose adjustment (or use of a different anticoagulant if renal insufficiency is severe). In patients taking fondaparinux for an extended period of time (eg, many months to years), renal function should be monitored periodically and the drug discontinued if the creatinine clearance decreases to &lt;30 <span class=\"nowrap\">mL/min</span> or shows a trend toward worsening. No dose reduction is needed for stable renal function and creatinine clearance &ge;30 <span class=\"nowrap\">mL/min</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Platelet count</strong> &ndash; Routine platelet count monitoring is not required with <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> administration, given the negligible risk for the development of heparin-induced thrombocytopenia (HIT) [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/30\" class=\"abstract_t\">30</a>]. However, patients at risk of developing thrombocytopenia for other reasons should undergo periodic monitoring of the platelet count.</p><p/><p class=\"headingAnchor\" id=\"H1601990015\"><span class=\"h1\">TRANSITIONING BETWEEN ANTICOAGULANTS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>From other anticoagulants to </strong><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> &ndash; The onset of action of fondaparinux is rapid, so it is generally started at the time another anticoagulant is discontinued. For patients on <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>, it is generally started when the international normalized ratio (INR) drops below 2.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>From </strong><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a><strong> to other agents</strong> &ndash; For patients receiving fondaparinux who will be transitioned to <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> in the setting of acute venous thromboembolism, we typically start warfarin and fondaparinux at the same time, and continue fondaparinux for at least five days and until the INR is in the therapeutic range. For patients receiving fondaparinux who will be transitioned to a direct acting oral anticoagulant (DOAC; eg, <a href=\"topic.htm?path=dabigatran-drug-information\" class=\"drug drug_general\">dabigatran</a>, <a href=\"topic.htm?path=apixaban-drug-information\" class=\"drug drug_general\">apixaban</a>, <a href=\"topic.htm?path=edoxaban-drug-information\" class=\"drug drug_general\">edoxaban</a>, <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a>), we typically start the DOAC 24 hours after the last dose of fondaparinux.</p><p/><p class=\"headingAnchor\" id=\"H900871597\"><span class=\"h1\">USE IN SPECIAL POPULATIONS</span></p><p class=\"headingAnchor\" id=\"H3648076479\"><span class=\"h2\">Extremes of weight</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the prophylactic setting, <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> is avoided for patients weighing &lt;50 kg; dosing of fondaparinux for patients &ge;50 kg is not adjusted according to patient weight.</p><p>In the therapeutic setting, dosing of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> is based on weight, as discussed above. (See <a href=\"#H6\" class=\"local\">'Dosing'</a> above.)</p><p class=\"headingAnchor\" id=\"H3264468542\"><span class=\"h2\">Renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, we do not use <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> for individuals with creatinine clearance &lt;30 <span class=\"nowrap\">mL/min</span>. Clinical trials of fondaparinux excluded individuals with creatinine clearance &lt;30 <span class=\"nowrap\">mL/min</span> or serum creatinine &gt;1.8 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/31\" class=\"abstract_t\">31</a>].</p><p>For individuals with creatinine clearance between 30 and 50 <span class=\"nowrap\">mL/minute,</span> <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> may be used with caution. This decision, and the specific dose and use of anti-factor Xa monitoring in this setting, is individualized. (See <a href=\"#H4004533291\" class=\"local\">'Monitoring'</a> above.)</p><p><a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">Unfractionated heparin</a> may be a better alternative in some patients with renal insufficiency. (See <a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects#H8476818\" class=\"medical medical_review\">&quot;Heparin and LMW heparin: Dosing and adverse effects&quot;, section on 'Unfractionated heparin'</a>.)</p><p class=\"headingAnchor\" id=\"H911896319\"><span class=\"h2\">Older adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> in individuals over the age of 75 years appears to be safe, provided that the patient weighs &gt;50 kg and has normal renal function. </p><p class=\"headingAnchor\" id=\"H488749887\"><span class=\"h2\">Pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical experience with <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> in pregnancy is less than that with low molecular weight (LMW) heparin, although use in pregnancy has been reported. Potential concerns include the longer half-life than LMW heparin and the possibility of underdosing as pregnancy weight increases; and a concern regarding potential passage of drug across the placenta to the fetus. We limit the use of fondaparinux in pregnancy to women who require an anticoagulant but are unable to tolerate heparin (eg, due to severe hypersensitivity reactions or heparin-induced thrombocytopenia [HIT]). Anticoagulation during pregnancy is discussed separately. (See <a href=\"topic.htm?path=use-of-anticoagulants-during-pregnancy-and-postpartum\" class=\"medical medical_review\">&quot;Use of anticoagulants during pregnancy and postpartum&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H299196713\"><span class=\"h2\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical experience with <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> in children is extremely limited, and we do not use fondaparinux in neonates or children. Appropriate alternatives are discussed in detail separately. (See <a href=\"topic.htm?path=management-of-thrombosis-in-the-newborn\" class=\"medical medical_review\">&quot;Management of thrombosis in the newborn&quot;</a> and <a href=\"topic.htm?path=venous-thrombosis-and-thromboembolism-in-children-treatment-prevention-and-outcome\" class=\"medical medical_review\">&quot;Venous thrombosis and thromboembolism in children: Treatment, prevention, and outcome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H756863694\"><span class=\"h1\">ADVERSE EFFECTS</span></p><p class=\"headingAnchor\" id=\"H2933616006\"><span class=\"h2\">Bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> increases the risk of bleeding, similar to other anticoagulants. Bleeding risk may be increased in those with underlying impairment of platelet function or coagulation (eg, liver disease, renal insufficiency, concomitant use of nonsteroidal anti-inflammatory drugs [NSAIDs]). Bleeding risk with fondaparinux may be of greater concern than with other anticoagulants because fondaparinux lacks a specific antidote or reversal agent.</p><p>A number of randomized trials comparing <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> with <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">unfractionated heparin</a> or low molecular weight heparin have documented comparable bleeding rates for the two treatments, typically on the order of 1 to 2 percent for major bleeding and 6 to 8 percent for clinically relevant non-major bleeding [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/21,31-37\" class=\"abstract_t\">21,31-37</a>].</p><p>Initial studies using higher prophylactic doses in the orthopedic setting found a higher rate of major bleeding [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/3\" class=\"abstract_t\">3</a>]. Bleeding risk in the perioperative setting was also greater if <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> was started sooner than six hours after skin closure [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/38\" class=\"abstract_t\">38</a>]. A review of data from several large randomized trials also noted increased risk of major bleeding in patients who were older, male, body weight &lt;50 kg, and impaired renal function [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/39\" class=\"abstract_t\">39</a>].</p><p class=\"headingAnchor\" id=\"H650797118\"><span class=\"h2\">Spinal/epidural hematoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Like other anticoagulants, <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> product labeling includes a Boxed Warning regarding the risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or undergoing spinal puncture [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/29\" class=\"abstract_t\">29</a>]. The risk is increased in those with indwelling epidural catheters, other drugs that impair hemostasis (eg, anti-platelet agents), traumatic or repeated epidural or spinal puncture, or a history of spinal surgery. According to the manufacturer, no spinal or epidural hematomas were reported when fondaparinux was withheld until at least two hours after removal of epidural catheters. An epidural hematoma has been reported related to multiple attempts at placing an epidural catheter.</p><p class=\"headingAnchor\" id=\"H4009381027\"><span class=\"h2\">Effect on coagulation testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> at prophylactic doses (eg, 2.5 mg once daily) does not appreciably prolong the prothrombin time (PT) or activated partial thromboplastin time (aPTT) [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/40,41\" class=\"abstract_t\">40,41</a>]; the aPTT may become prolonged at higher doses. There is no effect on the thrombin time, platelet function, or fibrinolysis.</p><p>As noted above, <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> does have anti-factor Xa activity; in the rare cases when anti-factor Xa activity is used for monitoring, the assay should be calibrated for fondaparinux. (See <a href=\"#H4004533291\" class=\"local\">'Monitoring'</a> above.)</p><p class=\"headingAnchor\" id=\"H831144\"><span class=\"h1\">MANAGEMENT AND PREVENTION OF BLEEDING</span></p><p class=\"headingAnchor\" id=\"H3331234277\"><span class=\"h2\">Bleeding/emergency surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are very few data to guide the management of bleeding or emergency surgery in patients anticoagulated with <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>, and no antidote exists. Most clinical data come from studies in healthy volunteers; there are no high quality data to show that available hemostatic therapies improve outcomes in patients with bleeding on fondaparinux [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/42\" class=\"abstract_t\">42</a>]. Our approach is based largely on preclinical data and an understanding of the mechanisms of action of the drug.</p><p>We individualize the management of bleeding, taking into account clinical variables for each patient and balancing the risks of bleeding complications with the risks of thrombosis from drug discontinuation or prohemostatic therapies. For those for whom a prohemostatic agent is deemed to be necessary, activated prothrombin complex concentrates (aPCC; eg, factor eight inhibitor bypassing agent [FEIBA]) or recombinant activated factor VII (rFVIIa) may provide some reversal of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> activity, although clinical data are limited to studies using in vitro coagulation testing rather than management of patients with bleeding [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/43,44\" class=\"abstract_t\">43,44</a>]. In the one study that compared these agents using coagulation testing in non-bleeding volunteers, aPCC was better able to normalize thrombin generation time than rFVIIa [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/44\" class=\"abstract_t\">44</a>]. The agents carry risks of thrombosis that must be balanced with the risks of bleeding for each patient. (See <a href=\"topic.htm?path=plasma-derivatives-and-recombinant-dna-produced-coagulation-factors#H16\" class=\"medical medical_review\">&quot;Plasma derivatives and recombinant DNA-produced coagulation factors&quot;, section on 'Activated PCCs'</a> and <a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Recombinant factor VIIa: Clinical uses, dosing, and adverse effects&quot;</a>.)</p><p>Andexanet alfa, a catalytically inactive form of factor Xa, is able to sequester direct factor Xa inhibitors, and is likely to be effective for reversing <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/45,46\" class=\"abstract_t\">45,46</a>]. It is not yet available for clinical use. (See <a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants#H1995289\" class=\"medical medical_review\">&quot;Management of bleeding in patients receiving direct oral anticoagulants&quot;, section on 'Antidotes under development'</a>.)</p><p>Measurement of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> drug levels using an anti-factor Xa assay calibrated to fondaparinux is appropriate in patients with major bleeding; however, this testing is not widely available. The degree of anticoagulation from fondaparinux can also be assessed using properly calibrated anti-factor Xa activity assays if needed. Fondaparinux may be dialyzable [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Additional general measures that should be taken in any patient with anticoagulant-associated severe bleeding are presented separately. (See <a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants\" class=\"medical medical_review\">&quot;Management of bleeding in patients receiving direct oral anticoagulants&quot;</a>.)</p><p>Evidence supporting a role for these agents includes the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>aPCC</strong> &ndash; In an preclinical (animal) model, aPCC was able to correct endogenous thrombin potential and lessen the duration of bleeding [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>rFVIIa</strong> &ndash; High doses of recombinant factor VIIa (90 <span class=\"nowrap\">mcg/kg)</span> were shown to partially normalize the prolonged aPTT, the endogenous thrombin potential, and prothrombin activation in vivo (as measured by prothrombin fragment F1+2 levels) in healthy volunteers given therapeutic doses of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/40,48\" class=\"abstract_t\">40,48</a>].</p><p/><p>In contrast to the therapies discussed above (aPCC, rFVIIa, andexanet alfa), <a href=\"topic.htm?path=protamine-sulfate-drug-information\" class=\"drug drug_general\">protamine sulfate</a> is not effective in reversing <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>; vitamin K has no role in fondaparinux reversal.</p><p class=\"headingAnchor\" id=\"H495387621\"><span class=\"h2\">Elective surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anticoagulant activity of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> persists for about three to five half-lives following discontinuation, or a period of two to four days in individuals with normal renal function.</p><p>Thus, major elective surgery requiring anticoagulant discontinuation should be delayed until two to four days after the last <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> dose. For certain low bleeding risk procedures, 24 hours may be sufficient. These time frames should be extended for individuals with renal insufficiency due to reduced drug clearance. Information regarding the bleeding risk of various procedures, the need for anticoagulant discontinuation, and the need for perioperative bridging anticoagulation is presented separately. (See <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;</a>.)</p><p>For individuals receiving postoperative thromboprophylaxis, the first postoperative dose is given six to eight hours after skin closure, as done in all of the major clinical trials. Providing the first postoperative dose on the morning after surgery appears to be an acceptable alternative, as demonstrated in the Flexibility in Administration of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> for Prevention of Symptomatic Venous Thromboembolism in Orthopedic Surgery (FLEXTRA) trial [<a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/49\" class=\"abstract_t\">49</a>]. In this trial, over 2000 patients were randomly assigned to receive the first dose of fondaparinux either six to eight hours after surgery or on the morning after surgery; at six weeks, the incidences of symptomatic venous thromboembolism and major bleeding were similar with either schedule (1.9 versus 1.8 percent and 1.2 versus 0.7 percent, respectively).</p><p class=\"headingAnchor\" id=\"H112801773\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-anticoagulation\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Anticoagulation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">Fondaparinux</a> is a synthetic anticoagulant based on the pentasaccharide sequence present in heparin and low molecular weight heparin. It acts as an indirect inhibitor of factor Xa (<a href=\"image.htm?imageKey=HEME%2F94856\" class=\"graphic graphic_figure graphicRef94856 \">figure 1</a>). Because of its size, fondaparinux does not inactivate thrombin (<a href=\"image.htm?imageKey=HEME%2F101832\" class=\"graphic graphic_figure graphicRef101832 \">figure 2</a>). The drug is renally metabolized and has a half-life of approximately 15 to 17 hours in individuals with normal renal function. (See <a href=\"#H2\" class=\"local\">'Pharmacology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical indications for <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> are discussed in separate topic reviews on venous thromboembolism (VTE) prophylaxis and treatment, superficial vein thrombosis, heparin-induced thrombocytopenia (HIT), percutaneous coronary interventions, and acute coronary syndromes. We do not use fondaparinux in children, individuals with creatinine clearance &lt;30 <span class=\"nowrap\">mL/min,</span> or individuals weighing &lt;50 kg (in the prophylactic setting). We generally avoid fondaparinux in pregnancy, unless there is a contraindication to heparin. (See <a href=\"#H1579490054\" class=\"local\">'Indications and contraindications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The typical dose of <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> is 2.5 mg subcutaneously once daily for VTE prophylaxis or acute coronary syndrome; and 5, 7.5, or 10 mg subcutaneously once daily for individuals weighing &lt;50 kg, 50 to 100 kg, or &gt;100 kg respectively for VTE treatment. Routine monitoring generally is not required. If needed, anti-factor Xa levels can be used provided the assay is calibrated for fondaparinux. Renal function should be checked periodically if fondaparinux use is prolonged. (See <a href=\"#H6\" class=\"local\">'Dosing'</a> above and <a href=\"#H4004533291\" class=\"local\">'Monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Like other anticoagulants, <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a> increases the risk of bleeding, and there is a Boxed Warning regarding the risk of <span class=\"nowrap\">spinal/epidural</span> hematoma. Bleeding risk was comparable to low molecular weight heparin in a number of VTE prophylaxis trials. Fondaparinux typically does not prolong the prothrombin time (PT) or activated partial thromboplastin time (aPTT) at the 2.5 mg per day dose, but the aPTT may become prolonged at higher doses. (See <a href=\"#H756863694\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no antidote for <a href=\"topic.htm?path=fondaparinux-drug-information\" class=\"drug drug_general\">fondaparinux</a>, and <a href=\"topic.htm?path=protamine-sulfate-drug-information\" class=\"drug drug_general\">protamine sulfate</a> is not effective for reversal. For patients with major or life-threating bleeding, the decision to use a prohemostatic agent, such as <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information\" class=\"drug drug_general\">activated prothrombin complex concentrate</a> (aPCC [eg, FEIBA]) or recombinant activated factor VII (rFVIIa), which carry a prothrombotic risk, must be balanced with the risk of bleeding; there are no data on the use of these agents in patients with fondaparinux-associated bleeding. Andexanet alfa is likely to be effective for reversing fondaparinux but is not yet available for clinical use. For elective surgery, we generally discontinue fondaparinux two to four days before the procedure. Postoperative thromboprophylaxis is generally initiated six to eight hours after skin closure, although giving the first dose the morning after surgery is also reasonable. (See <a href=\"#H831144\" class=\"local\">'Management and prevention of bleeding'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/1\" class=\"nounderline abstract_t\">Nijkeuter M, Huisman MV. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Curr Opin Pulm Med 2004; 10:338.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/2\" class=\"nounderline abstract_t\">Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res 2012; 129:407.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/3\" class=\"nounderline abstract_t\">Turpie AG, Gallus AS, Hoek JA, Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344:619.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/4\" class=\"nounderline abstract_t\">Olson ST, Bj&ouml;rk I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267:12528.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/5\" class=\"nounderline abstract_t\">Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87:831.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/6\" class=\"nounderline abstract_t\">Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001; 58 Suppl 2:S14.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/7\" class=\"nounderline abstract_t\">Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Hematol 2002; 9:422.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/8\" class=\"nounderline abstract_t\">Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106:3791.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/9\" class=\"nounderline abstract_t\">Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74:1384.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/10\" class=\"nounderline abstract_t\">Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8:114.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/11\" class=\"nounderline abstract_t\">Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105:139.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/12\" class=\"nounderline abstract_t\">Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88:ECR32.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/13\" class=\"nounderline abstract_t\">D'Amico EA, Villa&ccedil;a PR, Gualandro SF, et al. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1:2452.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/14\" class=\"nounderline abstract_t\">Harenberg J, J&ouml;rg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/15\" class=\"nounderline abstract_t\">Kuo KH, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93:999.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/16\" class=\"nounderline abstract_t\">Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011; 9:2389.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/17\" class=\"nounderline abstract_t\">Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356:2653.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/18\" class=\"nounderline abstract_t\">Elalamy I, Tribout B. Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal. J Thromb Haemost 2008; 6:1242.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/19\" class=\"nounderline abstract_t\">Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008; 6:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/20\" class=\"nounderline abstract_t\">Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thromb Haemost 2012; 108:394.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/21\" class=\"nounderline abstract_t\">Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/22\" class=\"nounderline abstract_t\">van Gogh Investigators, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357:1094.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/23\" class=\"nounderline abstract_t\">van Gogh Investigators, Buller HR, Cohen AT, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/24\" class=\"nounderline abstract_t\">Amadeus Investigators, Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371:315.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/25\" class=\"nounderline abstract_t\">Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs 2007; 16:431.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/26\" class=\"nounderline abstract_t\">Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8:722.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/27\" class=\"nounderline abstract_t\">Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011; 9:92.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/28\" class=\"nounderline abstract_t\">B&uuml;ller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379:123.</a></li><li class=\"breakAll\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021345s032lbl.pdf.</li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/30\" class=\"nounderline abstract_t\">Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/31\" class=\"nounderline abstract_t\">Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/32\" class=\"nounderline abstract_t\">B&uuml;ller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/33\" class=\"nounderline abstract_t\">B&uuml;ller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/34\" class=\"nounderline abstract_t\">Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359:1721.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/35\" class=\"nounderline abstract_t\">Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/36\" class=\"nounderline abstract_t\">Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/37\" class=\"nounderline abstract_t\">Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/38\" class=\"nounderline abstract_t\">Turpie A, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90:364.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/39\" class=\"nounderline abstract_t\">Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120:2006.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/40\" class=\"nounderline abstract_t\">Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/41\" class=\"nounderline abstract_t\">Smogorzewska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130:1605.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/42\" class=\"nounderline abstract_t\">Elmer J, Wittels KA. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfus Med 2012; 22:108.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/43\" class=\"nounderline abstract_t\">Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24:6.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/44\" class=\"nounderline abstract_t\">Desmurs-Clavel H, Huchon C, Chatard B, et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123:796.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/45\" class=\"nounderline abstract_t\">Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol 2015; 35:1736.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/46\" class=\"nounderline abstract_t\">Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373:2413.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/47\" class=\"nounderline abstract_t\">Corbonnois G, Martin M, Hacquard M, et al. Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats. Thromb Haemost 2013; 109:560.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/48\" class=\"nounderline abstract_t\">Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124:653.</a></li><li><a href=\"https://www.uptodate.com/contents/fondaparinux-dosing-and-adverse-effects/abstract/49\" class=\"nounderline abstract_t\">Colwell CW Jr, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21:36.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1319 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PHARMACOLOGY</a><ul><li><a href=\"#H1736413\" id=\"outline-link-H1736413\">Mechanism of action</a></li><li><a href=\"#H4208184561\" id=\"outline-link-H4208184561\">Metabolism</a></li><li><a href=\"#H1677004280\" id=\"outline-link-H1677004280\">Long-acting analogs</a></li><li><a href=\"#H3065436885\" id=\"outline-link-H3065436885\">Advantages and disadvantages compared with other anticoagulants</a></li></ul></li><li><a href=\"#H1579490054\" id=\"outline-link-H1579490054\">INDICATIONS AND CONTRAINDICATIONS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DOSING</a></li><li><a href=\"#H4004533291\" id=\"outline-link-H4004533291\">MONITORING</a></li><li><a href=\"#H1601990015\" id=\"outline-link-H1601990015\">TRANSITIONING BETWEEN ANTICOAGULANTS</a></li><li><a href=\"#H900871597\" id=\"outline-link-H900871597\">USE IN SPECIAL POPULATIONS</a><ul><li><a href=\"#H3648076479\" id=\"outline-link-H3648076479\">Extremes of weight</a></li><li><a href=\"#H3264468542\" id=\"outline-link-H3264468542\">Renal insufficiency</a></li><li><a href=\"#H911896319\" id=\"outline-link-H911896319\">Older adults</a></li><li><a href=\"#H488749887\" id=\"outline-link-H488749887\">Pregnancy</a></li><li><a href=\"#H299196713\" id=\"outline-link-H299196713\">Children</a></li></ul></li><li><a href=\"#H756863694\" id=\"outline-link-H756863694\">ADVERSE EFFECTS</a><ul><li><a href=\"#H2933616006\" id=\"outline-link-H2933616006\">Bleeding</a></li><li><a href=\"#H650797118\" id=\"outline-link-H650797118\">Spinal/epidural hematoma</a></li><li><a href=\"#H4009381027\" id=\"outline-link-H4009381027\">Effect on coagulation testing</a></li></ul></li><li><a href=\"#H831144\" id=\"outline-link-H831144\">MANAGEMENT AND PREVENTION OF BLEEDING</a><ul><li><a href=\"#H3331234277\" id=\"outline-link-H3331234277\">Bleeding/emergency surgery</a></li><li><a href=\"#H495387621\" id=\"outline-link-H495387621\">Elective surgery</a></li></ul></li><li><a href=\"#H112801773\" id=\"outline-link-H112801773\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/1319|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/94856\" class=\"graphic graphic_figure\">- Coagulation cascade anticoagulant effects</a></li><li><a href=\"image.htm?imageKey=HEME/101832\" class=\"graphic graphic_figure\">- Mechanism of action of heparins and fondaparinux</a></li></ul></li><li><div id=\"HEME/1319|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/107527\" class=\"graphic graphic_table\">- Possible contraindications to anticoagulation</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anticoagulant-therapy-in-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">Anticoagulant therapy in non-ST elevation acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-heparin-induced-thrombocytopenia\" class=\"medical medical_review\">Clinical presentation and diagnosis of heparin-induced thrombocytopenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects\" class=\"medical medical_review\">Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemostatic-abnormalities-in-patients-with-liver-disease\" class=\"medical medical_review\">Hemostatic abnormalities in patients with liver disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=heparin-and-lmw-heparin-dosing-and-adverse-effects\" class=\"medical medical_review\">Heparin and LMW heparin: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants\" class=\"medical medical_review\">Management of bleeding in patients receiving direct oral anticoagulants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-heparin-induced-thrombocytopenia\" class=\"medical medical_review\">Management of heparin-induced thrombocytopenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-thrombosis-in-the-newborn\" class=\"medical medical_review\">Management of thrombosis in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-lower-extremity-deep-vein-thrombosis-dvt\" class=\"medical medical_review\">Overview of the treatment of lower extremity deep vein thrombosis (DVT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">Perioperative management of patients receiving anticoagulants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=phlebitis-and-thrombosis-of-the-superficial-lower-extremity-veins\" class=\"medical medical_review\">Phlebitis and thrombosis of the superficial lower extremity veins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=plasma-derivatives-and-recombinant-dna-produced-coagulation-factors\" class=\"medical medical_review\">Plasma derivatives and recombinant DNA-produced coagulation factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-acutely-ill-hospitalized-medical-adults\" class=\"medical medical_review\">Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-venous-thromboembolic-disease-in-surgical-patients\" class=\"medical medical_review\">Prevention of venous thromboembolic disease in surgical patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=recombinant-factor-viia-clinical-uses-dosing-and-adverse-effects\" class=\"medical medical_review\">Recombinant factor VIIa: Clinical uses, dosing, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-anticoagulation\" class=\"medical medical_society_guidelines\">Society guideline links: Anticoagulation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-anticoagulants-during-pregnancy-and-postpartum\" class=\"medical medical_review\">Use of anticoagulants during pregnancy and postpartum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thromboembolism-anticoagulation-after-initial-management\" class=\"medical medical_review\">Venous thromboembolism: Anticoagulation after initial management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thromboembolism-initiation-of-anticoagulation-first-10-days\" class=\"medical medical_review\">Venous thromboembolism: Initiation of anticoagulation (first 10 days)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thrombosis-and-thromboembolism-in-children-treatment-prevention-and-outcome\" class=\"medical medical_review\">Venous thrombosis and thromboembolism in children: Treatment, prevention, and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=warfarin-and-other-vkas-dosing-and-adverse-effects\" class=\"medical medical_review\">Warfarin and other VKAs: Dosing and adverse effects</a></li></ul></div></div>","javascript":null}